Akorn, Inc. Responds to FDA Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl

December 16, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today provided the following response regarding FDA’s draft guidance on vancomycin hydrochloride (HCl) capsules.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Food and Drug Administration (FDA)